Ramipril treatment alters Ca2+ and K+ channels in small mesenteric arteries from Wistar-Kyoto and spontaneously hypertensive rats

American Journal of Hypertension

Volumn 15, Issue 10 I, 2002, Pages 879-890

  Cox, Robert H ^a   Lozinskaya, Irina ^a   Matsuda, Kyoko ^a   Dietz, Nancy J ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Force maintenance; Genetic hypertension; K+ channels; L type Ca2+ channels; Membrane mechanisms; Mesenteric arteries

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; IBERIOTOXIN; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; POTASSIUM ION; RAMIPRIL; TETRYLAMMONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTERY CONSTRICTION; ARTERY MUSCLE; ARTICLE; BODY WEIGHT; CALCIUM CURRENT; CELL ISOLATION; CHANNEL GATING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART WEIGHT; HYPERTENSION; MALE; MESENTERIC ARTERY; MUSCLE FIBER MEMBRANE POTENTIAL; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; RAT STRAIN; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 0036794669     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Frohlich ED: Clinical significance of hemodynamic findings in hypertension. Chest 1973;64:94-99.
2. Folkow B, Hallback R, Lundgren Y, Sivertsson R, Weiss L: Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res 1973;32(Suppl I):2-13.
3. Posmov YV, Orlov SN: Cell membrane alterations as a source of primary hypertension. J Hypertens 1984;2:1-6.
4. Triggle CR: Reactivity and sensitivity changes of blood vessels in hypertension, in Lee RMKW (ed): Blood Vessel Changes in Hypertension: Structure and Function, Vol. 1. Boca Raton, FL, CRC Press, 1989, p 25-44.
5. Hermsmeyer K, Erne P: Vascular muscle ion channels and cellular calcium regulation in hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. New York, Raven Press, Ltd., 1995, p 673-683.
6. Fleckenstein A, Fleckenstein-Grun G, Frey M, Zorn J: Calcium antagonism and ACE inhibition: Two outstandingly effective means of interference with cardiovascular calcium overload, high blood pressure, and arteriosclerosis in spontaneously hypertensive rats. Am J Hypertens 1989;2:194-204.
7. 45Ca influx in response to αl-adrenoceptor stimulation in spontaneously hypertensive rat caudal artery. J Cardiovasc Pharmacol 1987;10:205-212.
8. Bhalla RC, Webb RC, Singh D, Ashley T, Brock T: Calcium fluxes, calcium binding, and adenosine cyclic 3′,5′-monophosphate-dependent protein kinase activity in the aorta of spontaneously hypertensive and Kyoto Wistar normotensive rats. Mol Pharmacol 1978;14:468-477.
9. Tomera JF, Harakal C: Calcium fractions in aortic segments from hypertensive rabbits. J Cardiovasc Pharmacol 1982;4:592-600.
10. Atkinson J, Sautel M, Sonnay M, Fluckiger J-P, de Rivaz J-C, Boillat N, Piton M-C, Porchet P-A, Armstrong JM, Fouda A-K: Greater vasodepressor sensitivity to nicardipine in spontaneously hypertensive rats (SHR) compared to normotensive rats. NaunynSchmiedberg's Arch Pharmacol 1988;337:471-476.
11. Cattaneo EA, Rinaldi GJ, Gende OA, Venosa RA, Cingolani HE: Increased sensitivity to nifedipine of smooth muscle from hypertensive rats. J Cardiovasc Pharmacol 1986;8:915-920.
12. 2+ influx in spontaneously hypertensive rats is sensitive to calcium antagonists. Eur J Pharmacol 1987;138:147-149.
13. Rinaldi GJ, Cattaneo A, Mattiazzi A, Cingolani HE: Dissociation between calcium influx blockage and smooth muscle relaxation by nifedipine in spontaneously hypertensive rats. Circ Res 1987;60:367-374.
14. Takata Y, Hutchinson JS: Exaggerated hypotensive responses to calcium antagonists in spontaneously hypertensive rats. Clin Exp Hyperten 1983;A5:827-847.
15. Asano M, Aoki K, Matsuda T: Contractile effects of Bay k 8644, a dihydropryidine calcium agonists, on isolated femoral arteries from spontaneously hypertensive rats. J Pharmacol Exp 1986;239:198-205.
16. Kolias TJ, Chai S, Webb RC: Potassium channel antagonists and vascular reactivity in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1993;6:528-533.
17. + channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage. J Pharmacol Exp Therap 1995;275:775-783.
18. Cox RH, Lozinskaya IM: Augmented calcium currents in mesenteric artery branches of the spontaneously hypertensive rat. Hypertension 1995;26:1060-1064.
19. 2+ currents in small mesenteric artery myocytes from WKY and SHR. Hypertension 1997;29:1329-1336.
20. + current components in mesenteric artery myocytes from WKY and SHR. Am J Hyperten 2001;14:897-907.
21. + channel properties in freshly isolated myocytes from thoracic aorta of WKY and SHR. Am J Hypertens 1996;9:884-894.
22. + channels in genetic and nongenetic hypertension. Circ Res 1995;79:295-301.
23. 2+ entry, and gene expression in cerebral arteries of hypertensive rats. Am J Physiol 2001;281:H2559-H2567.
24. + current is enhanced in arterial membranes of hypertensive rats. Hypertension 1992;19:301-307.
25. + channels regulate the myogenic tone in the resting state of arteries from spontaneously hypertensive rats. Br J Pharmacol 1993;108:214-222.
26. Rusch NJ, Runnells AM: Remission of high blood pressure reverses arterial potassium channel alterations. Hypertension 1994;23(Part 2):941-945.
27. Cox RH, Haas KS, Moisey DM, Tulenko TN: Effects of endothelium regeneration on canine coronary artery function. Am J Physiol 1989;257:H1681-H1692.
28. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfleugers Arch 1981;391:85-100.
29. Nelson MT, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:C799-C822.
30. De Waard M, Gurnett CA, Campbell KP: Structural and functional diversity of voltage-activated calcium channels. Ion Channels 1996;4:41-87.
31. McEnery MW, Vance CL, Begg CM, Lee WL, Choi Y: Differential expression and association of calcium channel subunits in development and disease. J Bioenerg Biomembr 1998;30:409-418.
32. Chien AJ, Hosey MM: Post-translational modifications of beta subunits of voltage-dependent calcium channels. J Bioenerg Biomembr 1998;30:377-386.
33. 2+ concentrations. J Gen Physiol 1996;107:459-472.
34. + currents in arterial myocytes. Am J Physiol 1999;277:C51-C63.
35. Garwitz ET, Jones AW: Altered arterial ion transport and its reversal in aldosterone hypertensive rat. Am J Physiol 1982;243:H927-H933.
36. Furspan PB, Jokelainen PT, Sing CF, Bohr DF: Genetic relationship between a lymphocyte membrane abnormality and blood pressure in spontaneously hypertensive stroke prone and Wistar-Kyoto. J Hypertens 1987;5:293-297.
37. Korner PI, Bobik A: Cardiovascular development after enalapril in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1995;25(Part 1):610-619.
38. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H: Angiotensin II induces cardiac phenotyplc modulation and remodeling in vivo in rats. Hypertension 1995;25:1252-1259.
39. Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth cells. Circ Res 1988;62:749-756.
40. Kim S, Ohta K, Hamaguchi A, Miura K, Yukimura T, Iwao H: Suppression of vascular transforming growth factor-beta 1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats. Clin Exp Pharmacol Physiol 1995;22(Suppl 1):S355-356.
41. Berk BC, Corson MA: Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997;80:607-616.
42. Saward L, Zahradka P: Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997;81:249-257.
43. Schelling P, Fischer H, Ganten D: Angiotensin and cell growth: A link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15.
44. Schorb W, Erth G: Angiotensin II type I receptor induced signal transduction pathways as new targets for pharmacological treatment of the renin-angiotensin system. Basic Res Cardiol 1996;91:91-96.
45. Stoll M, Meffert S, Stroth U, Unger T: Growth or antigrowth: Angiotensin and the endothelium. J Hypertens 1995;13:1529-1534.
46. Rosendorff C: Vascular hypertrophy in hypertension: Role of the renin-angiotensin system. Mt Sinai J Med 1998;65:108-117.
47. Waeber B, Nussberger J, Brunner HR: Angiotensin-converting enyzme inhibitors in hypertension, In: Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. New York, Raven Press, Ltd., 1995, p. 2861-2875.
48. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchertti A: ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular mass in hypertension. Results of RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995;13:1325-1334.
49. Owens GK: Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987;9:178-187.
50. Wang DH, Yao A, Zhao H, DiPette DJ: Distinct mechanisms of modulation of angiotensin II type I receptor gene expression in heart and aorta. Hypertension 1997;29:1104-1108.
51. Lieve M, Gueret P, Gayet C, Roudaut R, Haugh MC, Delair S, Boissel JP: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995;25:92-97.
52. Wu JN, Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with angiotensin converting enzyme inhibitor captopril. Hypertension 1993;22:139-146.